Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CX-2009 · 1 trial · 5 indications
ORR is the proportion of patients in the efficacy-evaluable population with a best response of Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Central Radiology Review (CRR)
| Arm | Type | Description |
|---|---|---|
| ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative | EXPERIMENTAL | CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer |
| ARM B - CX-2009 Monotherapy, TNBC | EXPERIMENTAL | CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC) |
| ARM C - CX-2009 Combination therapy, TNBC | EXPERIMENTAL | CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC |
| Name | Type | Description |
|---|---|---|
| CX-2009 | DRUG | Intravenous administration of the CX-2009 of 6 mg/kg administered every 3 weeks (Q3W) |
| CX-072 | DRUG | Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W) |
INCLUSION CRITERIA: * Arm A: inoperable, locally advanced or metastatic HR-positive/HER2-negative breast cancer. Patients must have received 0 to 2 prior cytotoxic chemotherapy in the inoperable, locally advanced, or metastatic setting * Arm B and Arm C: inoperable, locally advanced or metastatic T...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
CX-2009 is an investigational small molecule developed by CytomX Therapeutics, Inc. (ticker CTMX) for the treatment of neoplasms, including breast cancers. It has been studied as a monotherapy and in combination with CX-072 in patients with advanced breast cancer. CX-2009 is in Phase 2 clinical development and is not approved for commercial use.
CX-2009 is being studied for the treatment of neoplasms, with its clinical program focused on advanced breast cancer. The Phase 2 trial enrolled patients with triple-negative breast cancer and hormone receptor positive, HER2 negative breast cancer. It was evaluated both as a monotherapy and in combination with CX-072.
CX-2009 is developed by CytomX Therapeutics, Inc., a biopharmaceutical company that trades under the ticker symbol CTMX. CytomX is the sponsor of the clinical program evaluating CX-2009 in advanced breast cancer, including its Phase 2 study of CX-2009 alone and in combination with CX-072.
CX-2009 is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 2 program evaluated CX-2009 as monotherapy and in combination with CX-072 in patients with advanced breast cancer, and that trial has been completed.
CX-2009 has been evaluated in the Phase 2 trial NCT04596150, titled a study to evaluate the safety and antitumor activity of CX-2009 monotherapy and in combination with CX-072 in advanced breast cancer. The trial enrolled 125 patients across the United States, South Korea, and Spain and has been completed.
The Phase 2 trial of CX-2009, NCT04596150, was a controlled study but was not randomized and not double blinded. It enrolled 125 patients aged 18 years and older of all sexes, with no healthy volunteers, and evaluated CX-2009 monotherapy and CX-2009 in combination with CX-072 in advanced breast cancer.